AstraZeneca (Alexion) to Acquire Amolyt Pharma for up to $1.05B

Alexion (AstraZeneca Rare Disease) Acquires LogicBio Therapeutics

November 16, 2022

Biotechnology

Alexion, AstraZeneca Rare Disease, has completed its acquisition of LogicBio Therapeutics, Inc. through a tender offer and merger, making LogicBio a wholly owned subsidiary. The deal is intended to accelerate Alexion's growth in genomic medicines by adding LogicBio's genomic medicine technology and rare disease R&D expertise; LogicBio's CEO Frederic Chereau will join Alexion as SVP, Strategy and Business Development.

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed the acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction at approximately $27.8 billion. The deal expands Amgen's inflammation and rare-disease portfolio by adding Horizon's medicines (including TEPEZZA, KRYSTEXXA and UPLIZNA) and strengthens Amgen's biologics R&D, manufacturing and global commercial capabilities.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Merck Acquires Acceleron Pharma for $11.5 Billion

September 30, 2021

Biotechnology

Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.

Sanofi Acquires Amunix Pharmaceuticals

December 21, 2021

Biotechnology

Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals for an upfront payment of approximately $1.0 billion plus up to $225 million in potential development milestones. The acquisition gives Sanofi Amunix’s Pro‑XTEN/XPAT/XPAC masking technology and a pipeline of conditionally activated T‑cell engagers and cytokine therapies (including lead candidate AMX‑818), expanding Sanofi’s immuno‑oncology capabilities.

Alexion Pharmaceuticals Acquires Portola Pharmaceuticals

May 5, 2020

Biotechnology

Alexion Pharmaceuticals agreed to acquire Portola Pharmaceuticals in a cash tender offer at $18.00 per share to add Portola’s Factor Xa inhibitor reversal agent Andexxa and diversify Alexion’s commercial portfolio beyond its complement franchise. The transaction, unanimously approved by both boards, was expected to close in the third quarter of 2020 and will be funded with Alexion’s cash on hand.